The Center for Biosimilars’ Post

Check out the latest findings from Biosimilars Council, shedding light on the challenges within Medicare Part D. Ensuring accessible healthcare means tackling #PBM obstacles head-on to enhance patient access to cost-effective treatment choices. https://lnkd.in/gDmQGE6G  

340B can be a powerful tool for healthcare equity by creating a ripple effect where drug savings for safety-net providers translate into expanded services and healthier communities. As technology to manage drug discounts bridges the gap between 340B and even MDRP, a more streamlined system could be effective in unlocking the program's full potential, allowing cost savings to flow directly to patients and fuel further progress in affordable care. #340B #Healthcare #MDRP

I'm excited to share that the Pharmacy Quality Alliance, in partnership with Inovalon, is evaluating the impact of the Medicare out-of-pocket cost cap for insulin on persistence to basal insulin. As of January 1, 2023, Medicare beneficiaries who receive insulin covered under Medicare Part D pay no more than $35 in out-of-pocket costs for a month’s supply. This analysis will provide early insights into the impact of the insulin price cap on patient persistence, and will use the PQA-endorsed Persistence to Basal Insulin(PST-INS) health plan performance measure to compare measure rates before and after the implementation of the cost cap in a large nationally representative sample of Medicare Advantage beneficiaries. Given the cost and burden of diabetes for patients and our health care system, this is an important opportunity to evaluate the correlation between recently enacted policy aimed at improving access to basal insulin and its real-world effects. This project is supported by Eli Lilly and Company and Novo Nordisk, and results from the analysis are expected in early 2025.

With healthcare landscapes constantly evolving, understanding the latest CMS requirements for Medication Therapy Management (MTM) programs is crucial. This comprehensive guide by Clarest provides a roadmap for payers to stay compliant and ahead of the curve. Learn about key changes, strategic implementation tips, and best practices to ensure your MTM programs meet CMS expectations. Stay informed and make informed decisions for your healthcare programs. Click the link below. #Healthcare #CMS #MTM #Payers #Compliance

Exploring the Ins and Outs of Buy-and-Bill: A Deep Dive into Provider-Administered Drugs. Our latest blog covers everything from the basics to best practices, offering valuable insights for healthcare providers and payers alike: https://lnkd.in/eE-_8_r4 #Healthcare #BuyAndBill #SpecialtyDrugs #PACS

Great Article on Buy and Bill for those looking to build their skill set.

Alagille Syndrome: Ipsen Secures European Union Approval for New Treatment Option Ipsen's Kayfanda (odevixibat) has been approved by the European Union for treating cholestatic pruritus in children with Alagille syndrome, a rare genetic liver disease causing severe itching. This approval, based on the successful ASSERT Phase 3 trial, showed significant improvements in itching and sleep quality. Kayfanda, already approved in the U.S. under the name Bylvay for progressive familial intrahepatic cholestasis, works by inhibiting ileal bile acid transport, reducing bile acid buildup. Ipsen is also investigating its use for biliary atresia, with potential for the drug to generate over $1 billion annually across multiple liver disease indications. For more details please click the link! https://lnkd.in/dqd2BMT2 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

No one should have to skip the care – or the medications – they need because of the #costofhealthcare and yet, numerous studies show that even those with employer-sponsored benefits often do. That is why I am so proud of #RxBenefits' transparent, client-aligned #pharmacybenefitoptimization model that enables self-funded plans provide valuable, affordable #pharmacybenefits. Curious to see if we can help you? Learn more here: https://lnkd.in/etjmdVT9

Read how hospital consolidation is reshaping healthcare, the tactics drugmakers use to block competition, why protecting Medicare Advantage is critical for seniors, and more in this week’s newsletter. https://lnkd.in/evkip5C7

Healthcare is at a crucial inflection point in both the US and Europe, with new policies like the Inflation Reduction Act (IRA) in the US and the EU Health Technology Assessment (HTA) Regulation reshaping the landscape. These policies aim to control drug prices, reduce out-of-pocket expenses, streamline decision-making processes, and ensure patient access to essential medications. At ISPOR 2024, experts Corey Ford (Cencora), Michael Drummond (University of York), Casper Paardekooper (Vintura, part of Cencora), and Kimberly Westrich (National Pharmaceutical Council) unpacked the transformative impacts of the IRA and EU HTA. The session provided an in-depth look at how these policies will impact stakeholders—biopharma companies, healthcare providers, payers, and patients, and how to navigate these complex reforms. Read this fantastic deep dive from The Evidence Base®to learn more. #EUHTA #InflationReductionAct #HealthTechnologyAssessment #MarketAccess